Multidrug-resistant tuberculosis in Europe, 2010-2011

TBNET

doi:10.3201/eid2103.141343

Multidrug-resistant tuberculosis in Europe, 2010-2011

TBNET

Department of Clinical Microbiology

85 Citations (Scopus)

Abstract

Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

Original language	English
Journal	Emerging Infectious Diseases
Volume	21
Issue number	3
Pages (from-to)	409-16
Number of pages	8
ISSN	1080-6040
DOIs	https://doi.org/10.3201/eid2103.141343
Publication status	Published - Mar 2015

Keywords

Adult
Antitubercular Agents/pharmacology
Comorbidity
Cross-Sectional Studies
Europe/epidemiology
Female
History, 21st Century
Humans
Incidence
Male
Microbial Sensitivity Tests
Middle Aged
Mycobacterium tuberculosis/drug effects
Population Surveillance
Risk Factors
Tuberculosis, Multidrug-Resistant/epidemiology

Access to Document

10.3201/eid2103.141343

Cite this

@article{9ea03be2bca145e5b411b5c7ba6fcf2b,

title = "Multidrug-resistant tuberculosis in Europe, 2010-2011",

abstract = "Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4\% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7\% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1\% were resistant to ≥1 second-line drug, 26.6\% were resistant to second-line injectable drugs, 17.6\% were resistant to fluoroquinolones, and 6.8\% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.",

keywords = "Adult, Antitubercular Agents/pharmacology, Comorbidity, Cross-Sectional Studies, Europe/epidemiology, Female, History, 21st Century, Humans, Incidence, Male, Microbial Sensitivity Tests, Middle Aged, Mycobacterium tuberculosis/drug effects, Population Surveillance, Risk Factors, Tuberculosis, Multidrug-Resistant/epidemiology",

author = "Gunar G{\"u}nther and \{van Leth\}, Frank and Sofia Alexandru and Neus Altet and Korkut Avsar and Didi Bang and Raisa Barbuta and Graham Bothamley and Ana Ciobanu and Valeriu Crudu and Manfred Davilovits and Martin Dedicoat and Raquel Duarte and Gina Gualano and Heinke Kunst and \{de Lange\}, Wiel and Vaira Leimane and Cecile Magis-Escurra and Anne-Marie McLaughlin and Inge Muylle and Veronika Polcov{\'a} and Emanuele Pontali and Christina Popa and Rudolf Rumetshofer and Alena Skrahina and Varvara Solodovnikova and Victor Spinu and Simon Tiberi and Piret Viiklepp and Christoph Lange and TBNET",

year = "2015",

month = mar,

doi = "10.3201/eid2103.141343",

language = "English",

volume = "21",

pages = "409--16",

journal = "Emerging Infectious Diseases ",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "3",

}

TY - JOUR

T1 - Multidrug-resistant tuberculosis in Europe, 2010-2011

AU - Günther, Gunar

AU - van Leth, Frank

AU - Alexandru, Sofia

AU - Altet, Neus

AU - Avsar, Korkut

AU - Bang, Didi

AU - Barbuta, Raisa

AU - Bothamley, Graham

AU - Ciobanu, Ana

AU - Crudu, Valeriu

AU - Davilovits, Manfred

AU - Dedicoat, Martin

AU - Duarte, Raquel

AU - Gualano, Gina

AU - Kunst, Heinke

AU - de Lange, Wiel

AU - Leimane, Vaira

AU - Magis-Escurra, Cecile

AU - McLaughlin, Anne-Marie

AU - Muylle, Inge

AU - Polcová, Veronika

AU - Pontali, Emanuele

AU - Popa, Christina

AU - Rumetshofer, Rudolf

AU - Skrahina, Alena

AU - Solodovnikova, Varvara

AU - Spinu, Victor

AU - Tiberi, Simon

AU - Viiklepp, Piret

AU - Lange, Christoph

AU - TBNET

PY - 2015/3

Y1 - 2015/3

N2 - Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

AB - Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

KW - Adult

KW - Antitubercular Agents/pharmacology

KW - Comorbidity

KW - Cross-Sectional Studies

KW - Europe/epidemiology

KW - Female

KW - History, 21st Century

KW - Humans

KW - Incidence

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Mycobacterium tuberculosis/drug effects

KW - Population Surveillance

KW - Risk Factors

KW - Tuberculosis, Multidrug-Resistant/epidemiology

UR - https://www.scopus.com/pages/publications/84923127789

U2 - 10.3201/eid2103.141343

DO - 10.3201/eid2103.141343

M3 - Journal article

C2 - 25693485

SN - 1080-6040

VL - 21

SP - 409

EP - 416

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 3

ER -

Multidrug-resistant tuberculosis in Europe, 2010-2011

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this